All In Biotech

Drug Trial Radar · NCT05383131

To Evaluate Drug-drug Interactions Between HEC585 and Pirfenidone or Nintedanib in Healthy Volunteers

A Single Center, Open Label Study to Evaluate Drug-drug Interactions Between HEC585 and Pirfenidone or Nintedanib in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: May 19, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

33

Actual

Start

Jun 23, 2021

Primary completion

Nov 30, 2021

Study completion Nov 30, 2021

Sponsor

Lead sponsor
Sunshine Lake Pharma Co., Ltd.Industry
Sponsor type
Industry
First posted
May 19, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

An open label study to evaluate drug-drug interactions between HEC585 and Pirfenidone or Nintedanib in healthy volunteers

Conditions

  • Idiopathic Pulmonary Fibrosis

Interventions

  • HEC585Drug

    Mulltiple doses of HEC585 for up to 10 days

  • PirfenidoneDrug

    Mulltiple doses of Pirfenidone for up to 3 days

  • NintedanibDrug

    Mulltiple doses of Nintedanib for up to 7 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cmax of HEC585 and PirfenidoneTime frame: 0~96 hour
  2. AUC of HEC585 and PirfenidoneTime frame: 0~96 hour
  3. Cmax of HEC585 and NintedanibTime frame: 0~96 hour
  4. AUC of HEC585 and NintedanibTime frame: 0~96 hour

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Xuhui Central Hospital

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.